VR真人彩票

Precision health

Inside a Mumbai lab using genomics for tuberculosis surveillance

How whole-genome sequencing can quickly detect TB drug resistance鈥攁nd help India wipe out TB in the next two years

Inside a Mumbai lab using genomics for tuberculosis surveillance
Dr. Camilla Rodrigues (middle row, fourth from left, in diamond-print sleeves) poses with her colleagues at P.D. Hinduja Hospital.
March 23, 2023

For more than 30 years, Dr. Camilla Rodrigues has fought the insidious disease tuberculosis (TB) with her dedicated team at the , a private, nonprofit hospital in Mumbai, India. Her philosophy is, 鈥淚t鈥檚 not just about diagnosis and prescribing drugs. It is about offering integrated patient care and improving the patient鈥檚 quality of life.鈥

Every year, TB causes worldwide. It鈥檚 the second-deadliest infectious disease after COVID-19. 鈥淯nfortunately, multidrug resistance is an increasing problem,鈥 Dr. Rodrigues says. 鈥淣early 500,000 new cases are detected each year globally, and TB could lose its curable status if something doesn鈥檛 change.鈥

In 2020, the World Health Organization (WHO) identified , which account for 86% of new TB cases鈥攁nd India is at the top of the list. At their large referral laboratory in Mumbai, Dr. Rodrigues and her team receive 150 to 175 TB samples per day.

Drug resistance on the rise
Back in 1990, as clinicians noticed an increase in patients with drug-resistant TB, the Hinduja lab began focusing on the disease, and Hinduja Hospital started investing in automated methods for culture-based phenotypic drug susceptibility tests as early as 1994.

In 2012, the Hinduja team published a showing compelling evidence of 鈥渢otal鈥 drug resistance in 12 patients in India鈥攎eaning there were twelve cases from one center that were resistant to all known treatments. This brought drug resistance back into focus, and the National Tuberculosis Control Programme implemented several changes and targets in its , including strengthening urban health care infrastructure to increase early diagnosis and stop transmission in cities.

鈥淒rug resistance was possibly underreported,鈥 Rodrigues explains. 鈥淚n 2015, a study by the National Programme performed at several sites across the country saw a 39% increase in incidence and a fivefold increase in drug resistance to rifampicin. This was a turning point, and subsequently India has deployed 3000 nucleic acid amplification testing centers across the country.鈥

Combatting multidrug-resistant TB
Without genomic science, there is no way to detect the mutations that cause multidrug resistance. But thanks to next-generation sequencing (NGS), scientists have unlocked the key to fighting multidrug-resistant (MDR) TB鈥攁nd in record time. 鈥淲hole-genome sequencing is gaining traction for TB surveillance,鈥 Rodrigues says. 鈥淚t can detect resistance to all drugs with a faster turnaround time.鈥

NGS enables highly accurate, high-throughput decoding of Mycobacterium tuberculosis genetic information, such as what mutations may exist in a particular strain that enable drug resistance. It鈥檚 a fast, sensitive, scalable, and culture-free drug susceptibility testing method that provides a comprehensive anti-TB drug resistance profile. Genomic sequencing for drug-resistant TB surveillance is one of the key initiatives in India鈥檚 National Strategic Plan to eliminate the disease by 2025.

Effective treatment ultimately depends on accurate and rapid diagnosis of variants that are resistant to all anti-TB drugs. The WHO has published a comprehensive catalogue of drug-resistant variants, so personalized treatment may be possible in the future. More remains to be done to characterize these variants, especially ones that are resistant to second-line drugs. Additional sequencing data is needed to continue to build the nation鈥檚 mutation catalogue.

The Hinduja team is leading the charge. Rodrigues envisions a future where every patient, no matter where they live, has access to a tailored treatment within three days.

鈥淧olitical will and funding count,鈥 she says. 鈥淚t took nine months to get a COVID vaccine on board. We should be fighting TB with the same fervor as COVID-19.鈥

VR真人彩票 is pleased to have supported Dr. Camilla Rodrigues and her tuberculosis team at P. D. Hinduja Hospital and Medical Research Centre with the provision of iSeq and MiSeq sequencers through the Seq and Treat trial, working with not-for-profit diagnostics organization .

To read more about tuberculosis surveillance, click here.

To learn about VR真人彩票 and GenoScreen Deeplex庐 Myc-TB Combo Kit, click here.

Recent Articles

VR真人彩票 careers: Expanding access to NGS in emerging markets
VR真人彩票 careers: Expanding access to NGS in emerging markets
New in the lab: Test driving the MiSeq i100 Plus
New in the lab: Test driving the MiSeq i100 Plus
Interrogating challenging genomic regions provides new answers for patients
Interrogating challenging genomic regions provides new answers for patients